Valeant to pay $85M for Brazilian supplement maker; Ipsen sales growth swallowed by charges;

@FiercePharma: Merck joins the select Big Pharma group that's reporting higher earnings and sales for Q4 and 2011--PR. Release | Follow @FiercePharma

> Valeant Pharmaceuticals ($VRX) bought a Brazilian supplements maker for $85 million in a deal expected to add to earnings immediately. News

> The French drugmaker Ipsen saw a 14.6% increase in fourth-quarter sales but took several charges against earnings, thanks to supply problems affecting a children's growth drug and downgraded sales at a U.S. biotech company it partially owns. Item

> The European Commission told Italy it must comply with EU rules on approving generic drugs for marketing, after makers of these meds complained of delays in market access. Story

> Impax Laboratories ($IPXL) licensed AstraZeneca's ($AZN) migraine therapy Zomig in the U.S. for $130 million plus future royalties, aiming to build sales of the drug's nasal-spray formulation. Article

> Sen. Chuck Grassley (R-Iowa) wrote the FDA to demand an explanation of employees' claims that they were harassed after blowing the whistle on device-approval shortfalls. More

Biotech News

@FierceBiotech: CROs jump into 2012 with big contracting momentum. Article | Follow @FierceBiotech

@JohnCFierce: Interesting to see that AZ will retreat to Boston and Cambridge, U.K. as it downsizes neuro R&D. Less has been more for Boston. | Follow @JohnCFierce

@FierceMedDev: French officials urge tougher EU rules after PIP affair. Story | Follow @FierceMedDev

@MarkHFierce: Alzheimer's spreads like an infection through a distorted protein. Columbia and Harvard made the finding. Huge. More | Follow @MarkHFierce

> UPDATED: AstraZeneca cutting 2,200 R&D jobs, slashing neuroscience in restructuring. News

> Pharma defeats biotech push for rapid approval program. Story

> Is Lilly betting the farm on its high-stakes Alzheimer's gamble? Article

> AB soars on promising survival data from Phase II tumor study. Piece

> Czechs beef up investment in biotech research. Item

Manufacturing News

> Roche plant spared from sale runs into GMP issues. More

> Pakistan drug manufacturers make plea for oversight. Story

> Amylin's OH plant prepped for Bydureon's U.S. debut. Article

Vaccines News

> Universal flu vaccine might be step closer. Story

> Study: Gardasil does not cause autoimmune disease. Article

> First hookworm vaccine enters clinical trials. More

> Ovarian cancer vaccine clinical trial begins enrollment. Item

> Evolving bacteria evade vaccines. Story

CRO News

> Lonza trouble may trigger big writedown at Ipsen. Article

> Pew pushes for better FDA oversight of global supply chain. More

> Analysts project red-hot Euro growth for CMO market. News

> Parexel plans more hires as it focuses on strategic players, biotech. Story

And Finally... Trouble in your team meeting? Someone's testosterone levels might be to blame. Report

Suggested Articles

Regeneron and Sanofi hope their PD-1 inhibitor Libtayo will be the first immuno-oncology treatment approved to treat basal cell carcinoma.

With its phase 3 trial moving right along, Moderna is expecting efficacy data in November—likely after Pfizer and BioNTech, but before everyone else.

Pfizer, GSK, BIO and others are all planning vaccine messages for fall.